Accepted: 11 August 2021
First Online: 16 September 2021
: Y.Y. has received consulting fees from Amgen and research support from Amgen, BMS and Genentech. G.H. has received research grant, lecture fees and fees for serving on an advisory board from Celgene; consulting fees from Bayer, Johnson & Johnson and UCB Pharma; and lecture fees from Abbvie, Amgen, Novartis and UCB Pharma. B.B. has received consulting fees from AbbVie/Allergan, Alimera, Horus Pharma, Novartis, Santen and Thea. All other authors declare no competing interests.